Evotec (NASDAQ:EVO) Shares Gap Up – Time to Buy?

Evotec SE (NASDAQ:EVO) shares gapped up prior to trading on Tuesday . The stock had previously closed at $3.30, but opened at $3.39. Evotec shares last traded at $3.40, with a volume of 17,661 shares changing hands.

Evotec Trading Down 3.0 %

The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43. The company’s fifty day simple moving average is $3.73 and its two-hundred day simple moving average is $4.06.

Institutional Trading of Evotec

A number of institutional investors have recently bought and sold shares of EVO. Lighthouse Investment Partners LLC bought a new stake in Evotec during the fourth quarter worth about $166,000. DCF Advisers LLC lifted its holdings in shares of Evotec by 5.9% during the fourth quarter. DCF Advisers LLC now owns 229,871 shares of the company’s stock worth $956,000 after purchasing an additional 12,816 shares during the period. CSS LLC IL bought a new stake in Evotec in the fourth quarter valued at approximately $50,000. Bank of America Corp DE boosted its position in shares of Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after purchasing an additional 9,289 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new position in shares of Evotec during the 4th quarter valued at $27,000. Institutional investors own 5.81% of the company’s stock.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.